详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

LncRNA DHRS4-AS1 Inhibits the Stemness of NSCLC Cells by Sponging miR-224-3p and Upregulating TP53 and TET1.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, [2]School of Laboratory Medicine/Sichuan Provincial Engineering Laboratory for Prevention and Control Technology of Veterinary Drug Residue in Animal-Origin Food, Chengdu Medical College, Chengdu, China

出处：

DOI：

ISSN：

关键词： non-small cell lung cancer DHRS4-AS1 miR-224-3p TP53 TET1 cancer cell stemness

摘要：

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. This study aimed to examine the roles of DHRS4-AS1/miR-224-3p signaling in the cancer cell stemness of NSCLC. Real-time PCR showed that DHRS4-AS1 was downregulated in cancerous tissues, and bioinformatics analysis revealed that high DHRS4-AS1 expression indicated a good prognosis for NSCLC patients. Sphere and colony formation assays showed that DHRS4-AS1 overexpression significantly suppressed NSCLC cell colony formation and stem cell-like properties. DHRS4-AS1 also abrogated the expression of OCT4, SOX2, CD34, and CD133, markedly inhibited the expression of epithelial-mesenchymal transition (EMT)-related factors, N-cadherin, ZEB1, and Vimentin, and increased E-cadherin expression in spheres. Furthermore, luciferase reporter assays and real-time PCR analysis demonstrated that DHRS4-AS1 and miR-224-3p were antagonistically repressed in NSCLC cells. RNA immunoprecipitation (RIP) analysis revealed that DHRS4-AS1 interacted with miR-224-3p. DHRS4-AS1 partially reversed the miR-224-3p-decreased TP53 and TET1, resulting in the inhibition of tumor growth in vivo. Finally, TP53 and TET1 were antagonistically regulated by DHRS4-AS1 and miR-224-3p in NSCLC cells. In conclusion, TP53- and TET1-associated DHRS4-AS1/miR-224-3p axis is an essential mechanism by which NSCLC modulates cancer cell stemness. Copyright © 2020 Yan, Zhao, Xu, Li, Li, Liu, Shi and Wu.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版中科院分区表Review为是的期刊

：

大类 | 2 区生物学

小类 | 2 区发育生物学 3 区细胞生物学

最新[2023]版：

大类 | 2 区生物学

小类 | 2 区发育生物学 3 区细胞生物学

第一作者：

第一作者机构： [1]Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China,

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. [2]The NEDD4/FLRT2 axis regulates NSCLC cell stemness [3]Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. [4]Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness [5]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [6]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [7]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [8]非小细胞肺癌小细胞转化的分子特征及治疗进展 [9]Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing. [10]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells